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The Ca2+-sensing receptor (the CaSR), a G-protein-coupled receptor, regulates Ca2+ homeostasis in the body by monitoring ex-
tracellular levels of Ca2+ ([Ca2+]o) and responding to a diverse array of stimuli. Mutations in the Ca
2+-sensing receptor result in 
hypercalcemic or hypocalcemic disorders, such as familial hypocalciuric hypercalcemia, neonatal severe primary hyperpara-
thyroidism, and autosomal dominant hypocalcemic hypercalciuria. Compelling evidence suggests that the CaSR plays multiple 
roles extending well beyond not only regulating the level of extracellular Ca2+ in the human body, but also controlling a di-
verse range of biological processes. In this review, we focus on the structural biology of the CaSR, the ligand interaction sites 
as well as their relevance to the disease associated mutations. This systematic summary will provide a comprehensive explora-
tion of how the CaSR integrates extracellular Ca2+ into intracellular Ca2+ signaling. 
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After Sydney Ringer serendipitously discovered calcium 
(Ca2+) to be essential for the contraction of isolated hearts in 
1883 [1], Ca2+ has received substantial attention and re-
search on Ca2+ has grown at an exponential rate as it was 
recognized that Ca2+ is a universal carrier of biological in-
formation [2]. Ca2+ controls matters of life and death as it 
modulates the process of fertilization as well as apoptosis. 
Before the discovery of the calcium-sensing receptor (the 
CaSR), Ca2+ was mainly considered as a crucial second 
messenger through rapid yet efficient alterations in the in-
tracellular calcium; it modulates extensive molecular sig-
naling components through calcium channels and exchang-
ers as well as pumps [3]. When Ca2+ plays a role as first 
messenger for the CaSR, it integrates calcium signaling 
from changes in the extracellular Ca2+ concentration 
([Ca2+]o) to intracellular signaling networks that are criti-
cally important for many (patho)physiological processes, 
including cardiovascular remodeling, tumor cell migration 
and cancer metastasis [47]. Ca2+-sensing receptors (the 
CaSRs) along with 14 other members of family C of the G 
protein-coupled receptors (cGPCRs), i.e., the metabotropic 
glutamate receptors (mGluR) and -aminobutyric acid 
(GABA)B receptors, cooperatively respond to small changes 
in [Ca2+]o to activate multiple signaling pathways. The 
cGPCRs are also integrators of diverse extracellular signal-
ing molecules, including metabolites neurotransmitters (i.e., 
amino acids), pheromones, and sweet substances using their 
conserved long N-terminal extracellular domains (ECD) 
with a Venus Fly Trap (VFT) motif that contains a flexible 
hinge region. The CaSRs distributed in multiple organs play 
a central role in regulating [Ca2+]o homeostasis [812] as 
well as monitoring protein/amino acid metabolism by sens-
ing amino acids, especially aromatic amino acids, in blood 
and related extracellular fluids.  
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Although Ca2+ is considered as a universal signal for the 
regulation of cells, it can be toxic to cells if it stays too long 
at an excessively high concentration. Pulsatile Ca2+ signals 
have evolved to prevent such toxicity. Two major mecha-
nisms are involved in the production of the temporal Ca2+ 
signals that can, in turn, lead to more complex downstream 
signaling. The first one happens in skeletal and cardiac cells 
when the intracellular Ca2+ signaling pulses are produced on 
demand as the cells respond to periodic stimulation that 
leads to membrane depolarization. This kind of signal can 
be observed in muscle cells when they contract and also in 
nerve terminals when neurotransmitters are released upon a 
brief localized pulse of intracellular Ca2+ [2]. The second 
type appears as an oscillation when the cells receive con-
tinuous stimulation over a period of time. This rhythmic 
Ca2+ signal has a wide range of frequencies that are tightly 
related to a variety of cellular responses (i.e., gene expres-
sion, fertilization, cell growth, transmitter release, etc.) [13].   
In this review, we will review the structural information 
known about the CaSR and explore its molecular properties 
as an important therapeutic target in disorders with abnor-
mal [Ca2+]o homeostasis.  
1  Biological roles of the CaSR 
It has been well known that the serum Ca2+ concentration 
can regulate the secretion of parathyroid hormone (PTH). In 
1993, Dr. Edward M. Brown and coworkers [14] cloned the 
receptor that is primarily responsible for this type of regula-
tion from the bovine parathyroid gland. The receptor was 
given the name “calcium-sensing receptor” (the CaSR/CaR). 
The previously observed cytosolic calcium changes in par-
athyroid cells, as well as in other in vitro expression sys-
tems, were triggered by changes in the serum calcium con-
centration and are characteristic “signatures” of the CaSR’s 
activities [15,16]. A unique characteristic of the CaSR is the 
high degree of cooperativity of its Ca2+-dependent activa-
tion, which tightly controls the secretion of parathyroid 
hormone when the receptor is exposed to changes in serum 
Ca2+ concentration within its responsive range [14]. The 
CaSRs expressed in various species are highly conserved, 
indicating the biological importance of this receptor in reg-
ulating physiological functions among living organisms.  
The major function of the CaSR is to maintain calcium 
homeostasis through balancing the ingestion and absorption 
of calcium from the gastrointestinal tract, excretion of cal-
cium by the urinary system and the breakdown and for-
mation of bone [17,18] (Figure 1). The CaSR is mainly ex-
pressed in the parathyroid and thyroid glands, as well as in 
other tissues mentioned above. The CaSR regulates PTH 
secretion from parathyroid glands and calcitonin secretion 
from thyroidal C-cells upon detection of variations in the 
calcium concentration in the extracellular fluid [17]. 
Moreover, the CaSR has its specific roles in different 
tissues. As mentioned in the last section, the CaSR was first 
discovered in parathyroid cells. The main function of the 
receptor is to mediate the negative feedback of PTH secre-
tion upon stimulation by various agonists [14]. Most of the 
CaSR expressed in parathyroid cells is located in caveolae, 
where a significant number of signaling molecules, as well 
as scaffolding proteins, reside [19]. Similarly, one of the 
critical roles the CaSR expressed in the kidney is in main-
taining calcium homeostasis [20]. However, the CaSR along 
different parts of the nephron (e.g., the proximal tubule, 
thick ascending limb, etc.) may have specific functions 
[21,22]. 
The CaSR is also found in the gastrointestinal tract, in-
cluding the esophagus, stomach, small intestine, and colon 
[23,24]. The activity of the CaSR has been reported to be 
associated with increased phosphorylation of ERK, intra- 
 
 
Figure 1  Systematic regulation of Ca2+ homeostasis in human body. Two major circulating hormones (PTH and CT) regulate Ca2+ homeostasis via several 
primary organs. If the Ca2+ level is too low, PTH is released from parathyroid glands. It then stimulates Ca2+ uptake from intestines, increases the rate of Ca2+ 
release from bone and the rate of Ca2+ reabsorption in the urinary system. If the Ca2+ level is too high, the opposite regulation will occur to control the blood 
Ca2+ level. Thus, the blood Ca2+ is strictly maintained between 1.11.4 mmol L1. 
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cellular calcium mobilization, secretion of IL-8, gastric acid 
[2527] and cell proliferation and differentiation [28,29].  
The CaSR has been identified in bone as demonstrated 
by various techniques [30]. Both osteoblasts and osteo-
blastic cell lines, such as MC3T3-E1 cells, as well as osteo-
clasts are reported to express the CaSR. The receptor is in-
volved in osteoblast proliferation, likely via JNK signaling 
[31,32], and participates in both differentiation and apopto-
sis of osteoclasts through the PLC pathway [33]. Activation 
of the CaSR is also believed to inhibit the bone resorbing 
activity of osteoclasts [34].     
Experiments using immunocytochemistry showed that 
the CaSR is widely distributed in the central nervous system 
with quite a diverse pattern [35]. In the nervous system, the 
CaSR can also form heterodimers with other family C 
GPCRs [36,37]. It has been proposed that the CaSR may 
play a crucial role in regulating ion currents that mediate the 
initiation of action potentials and the associated neuronal 
depolarization [38]. The CaSR in the hippocampus has been 
reported to regulate both Ca2+-permeable, nonselective cat-
ion channels as well as Ca2+-activated K+ channels 
[35,39,40].  
The CaSR is also detected in cardiac tissue by various 
techniques, including RT-PCR and immunohistochemistry 
[41]. A few pathological processes have been found to be 
associated with an increased expression level of the CaSR, 
for instance, angiotensin II-induced cardiac hypertrophy [42] 
and hypoxic-oxygenation-treated cardiac myocytes [43].  
2  The structural biology of the CaSR 
The CaSR expressed in pcDNA-CaSR-transfected human 
embryonic kidney (HEK293) cells exhibits similar expres-
sion patterns as the CaSR proteins identified in parathyroid 
cells [44]. The Western blot results of the CaSR extracted 
from HEK293 cells showed several immunoreactive bands 
using antibodies specific for the CaSR. The minor band at 
120 kD corresponds to the non-glycosylated monomeric 
form of the protein, the major band at 140 kD is the high 
mannose form, while another major band at 160 kD repre-
sents the complex carbohydrates form of the monomeric 
CaSR [44,45]. Additional bands at higher molecular mass 
(350 kD) correspond to the dimeric forms of the receptor. 
The CaSR that is expressed on the cell membrane is the 
mature receptor that only accounts for a small portion of the 
total cellular protein [46].  
The CaSR comprises four major parts in terms of its 
structure: a large N-terminal extracellular domain (ECD), a 
cysteine-rich domain linking the ECD to the first trans-
membrane helix, a seven transmembrane domain and the 
intracellular C-terminal. The major function of the CaSR in 
vivo is regulating the calcium concentration in the human 
blood. Upon stimulation with Ca2+ or other polycations, a 
number of intracellular signal transduction pathways are 
activated (Figure 2). Among them, the phosphoinositide- 
specific phospholipase C (PI-PLC) and extracellular sig-
nal-regulated kinases (ERK1/2) have been widely applied to 
the investigation of CaSR activity [48,49].
 
 
Figure 2  Calcium-sensing receptor-regulated intracellular signaling pathways. The interaction between Ca2+ and CaSR results in activation of phosphati-
dylinositol-specific phospholipase C (PLC) through recruitment of the Gq/11 proteins. PLC hydrolyzes phosphatidylinositol-4,5-bisphosphate 
[PtdIns(4,5)P2] to inositol-1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG). InsP3 triggers the release of calcium from the endoplasmic reticulum (ER) 
calcium store via the InsP3 receptor (IP3R) embedded in the ER membrane. Calmodulin (CaM) binds to the C-terminus of CaSR to maintain proper respon-
siveness of intracellular Ca2+ responses to changes in extracellular Ca2+ and regulate cell surface expression of the receptor [47]. 
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Like other members in the family C GPCR proteins, the 
CaSR possesses the signature large N-terminal ECD. The 
low but significant amino acid sequence identity between 
the family C GPCRs and a group of bacterial periplasmic 
amino acid-binding proteins suggest evolutionary relevance. 
Indeed, the crystal structure of the ECD of rat metabotropic 
glutamate receptor (mGluR1) showed a bi-lobed Ve-
nus-flytrap-like structure (VFT), which is fully consistent 
with the structure of the bacterial periplasmic amino ac-
id-binding proteins, switching between “open” and “closed” 
conformational states upon releasing or binding their en-
dogenous agonists (Figure 3A) [50]. The alignment of the 
amino acid sequence of the CaSR ECD (AA36-AA513) 
with mGluRs and the bacterial periplasmic amino acid- 
binding proteins results in a proposed VFT model of the 
CaSR ECD with the N-terminal lobe I connecting to the 
C-terminal lobe II [51]. However, the alignment also shows 
four segments in lobe I that do not align with the bacterial 
periplasmic amino acid-binding protein resulting in four 
unstructured loops (IIV) [52]. Only a large part of loop III 
(from residues 365385) could be deleted without reducing 
the activity of the CaSR while truncation in the other four 
loops resulted in a low surface expression of the receptor 
[52].  
The VFT structure of mGluR1 forms a homodimer as 
verified by the 3D structure of rat mGluR1 VFT. The in-
termolecular disulfide requires a conserved cysteine in loop 
2, and the equivalent residues in the CaSR are C129 and 
C131 [51,53]. Experiments mutating the two cysteines sug-
gested that disruption resulted in failure to form disulfide 
bonds, but did not affect the formation of dimer [54]. Other 
cysteines in the ECD of the CaSR including C60–C101, 
C358–C395 and C437–C449 form three intramolecular di-
sulfides, which are critical for the CaSR expression and 
activity [55]. 
All members of the GPCR family C have a conserved 
nine-cysteine structure at the end of the C-terminal domain 
of the ECD and before the seven transmembrane domains 
except the GABAB receptor [56]. For the CaSR, the region 
possesses about 84 residues. Mutations of any of the nine 
Cys to Ser dramatically impair the surface expression and 
the function of the CaSR. Deletion of this Cys-rich domain 
results in the abrogation of the CaSR activity.     
The CaSR contains a seven transmembrane domain 
(7TM) similar to the other proteins in the GPCR superfami-
ly. It is believed that agonist binding to GPCRs will lead to 
conformational changes of the 7TM -helices, further in-
ducing alterations in intracellular loops as well as the 
C-terminal domain, thereby triggering the downstream sig-
naling pathways. The crystal structure of rhodopsin (a 
GPCR Family A protein), which has a 7TM domain like the 
GPCRs, has been reported. However, extreme caution is 
needed when extrapolating the CaSR 7TM structure from 
rhodopsin as proteins from family C share low sequence 
identity with proteins from family A. The six prolines in the 
transmembrane domain are important to maintain the kinks 
in the transmembrane helices. Mutations of some prolines 
(P748R, P823A) [57,58] impair receptor function.  
The intracellular domain of the CaSR contains 216 ami-
no acids that do not show high conservation among species 
[59]. Two regions in this intracellular tail are homologous 
between species: one from 863925 located at the proximal 
of C-tail that is pivotal in surface expression; the other from 
960984 that is involved in interacting with downstream 
proteins [6062]. Three potential protein kinase C (PKC) 
phosphorylation sites are present in the intracellular domain: 
T888, S895 and S915 are involved in regulating receptor 
activity [63]. Especially, T888 plays a significant role in the 
negative regulation of the CaSR’s activity by PKC.  
Along with the PKC phosphorylation sites, two other 
residues participate in protein kinase A phosphorylation: 
S899 and S900. Studies of these two sites indicate minor 
effects of PKA phosphorylation on the modulation of the 
CaSR activity [64], but the phosphorylation at S899 may 
regulate the recognition of an arginine-rich region in the 
proximal carboxyl terminus of the CaSR, which contributes 
to intracellular retention of the receptor [65].  
3  The ligand binding sites on the CaSR 
3.1  Prediction of Ca2+-binding sites in the CaSR  
The identification of potential Ca2+ binding sites on the 
CaSR is challenging not only because of the lack of a crys-
tal or solution structure of the receptor but also owing to the 
limitations of current techniques regarding direct measure-
ment of Ca2+ binding to the receptor. The fast off rate of 
Ca2+ due to its weak binding affinity also hinders the char-
acterization, as even with proteins that have their crystal 
structure solved (e.g., mGluR1), the detection of Ca2+- 
binding sites may still be elusive [66]. Our lab as well as a 
few other groups have generated homology model struc-
tures of the extracellular domain of the CaSR based on the 
crystal structures of mGluR1, and have identified predicted 
Ca2+-binding sites using these models [67,68]. One of the 
predicted Ca2+-binding sites has been proposed by both our 
group [69] and Silve et al. [67]. This Ca2+-binding site, later 
referred to as Site 1, is located in the hinge region between 
lobe I and lobe II of the CaSR ECD, and is composed of 
residues Ser147, Ser170, Asp190, Tyr218 and Glu297. Mu-
tations of these five residues on the receptor resulted in im-
paired receptor function demonstrated by both groups. In 
our first paper about the CaSR, we also identified two addi-
tional Ca2+ binding sites using grafting approaches. One of 
them is located in lobe I, containing residues Glu378, 
Glu379, Thr396, Asp398 and Glu 399, and is referred to as 
Site 5 in the latter studies. The other one is on lobe II, in-
volving resides Glu224, Glu228, Glu229, Glu231 and 
Glu232, which is named Site 3. Peptide sequences of the 
CaSR containing these predicted Ca2+ binding site were  
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inserted into CD2 protein. The latter is known as a non 
Ca2+-binding protein, and the chimeric proteins were used 
for verifying their calcium-binding capabilities using vari-
ous biophysical approaches. Following these findings, our 
lab further used subdomain approaches to verify the poten-
tial Ca2+-binding sites on the ECD, including the three pre-
viously identified Ca2+-binding sites and two additional 
Ca2+-binding sites: Site 2, which is composed of residues 
Glu215, Leu242, Ser244, Asp248, Gln253; and Site 4, 
which contains residues Glu350, Glu353, Glu354, Asn386, 
and Ser388. The three subdomains, comprising residues 
132–300, 185–324, and 323–494 were expressed in a bacte-
rial system. Ca2+-induced conformational changes were ob-
served in spectroscopic studies using 8-anilino-1-    
naphthalenesulfonic acid (ANS) fluorescence, intrinsic 
tryptophan spectra as well as nuclear magnetic resonance 
[69]. Moreover, the studies using subdomains of the CaSR 
also suggested multiple cooperative metal-binding process-
es as revealed by Tb3+ luminescence energy transfer studies 
and mutagenesis work on the putative Ca2+-binding sites 
[69]. More recently, using mutagenesis, we have shown that 
mutations in Ca2+-binding site 1, such as Glu297 and 
Tyr218, not only disrupted the Ca2+-sensing capacity of the 
CaSR but also had an impact on the positive homotropic 
cooperative interactions of Ca2+ with other Ca2+-binding 
sites [70]. Moreover, molecular dynamic simulation results 
revealed that residues located at Site 1 showed strong cor-
related motions with other residues in the other four sites. 
These observations demonstrated the molecular connectivi-
ty among the five predicted Ca2+-binding sites with Site 1 
playing a central role and have provided a description at the 
atomic level of the cross-talk between different Ca2+-  
binding sites of the CaSR.   
The transmembrane domain of the CaSR (7TM) has been 
suggested to contain additional Ca2+-binding sites in a few 
studies [12,71]. Hauache et al. [12] engineered a chimeric 
receptor with the extracellular domain of rhodopsin linked 
with the transmembrane domain and intracellular C-tail of 
the CaSR to show that the chimeric receptor could be ex-
pressed at the cell surface and was able to response to ex-
tracellular Ca2+ in the presence of NPS R-568, a positive 
allosteric modulator of CaSR. Hu et al. [58] analyzed 12 
naturally occurring activating mutations of the CaSR locat-
ed in the 7TM domain and found that five of them were 
located at the junction of TM helices 6 and 7 between resi-
dues Ile819 and Glu837. They utilized alanine-scanning 
mutagenesis and revealed that Ile819-Glu837 played a key 
role in CaSR activation by Ca2+. The same group later found 
that substitution of three of the five acidic amino acids with 
alanine in the extracellular loop 2, Asp758, Glu759 and 
Glu767, increased the activity of the CaSR [71]. These 
findings indicated that Ca2+ could tune the receptor’s func-
tion partially through the transmembrane domain.  
3.2  Amino acid-binding by the CaSR 
As a multimodal, multimetabolic sensor, the CaSR regulates 
whole body calcium homeostasis not only through its re-
sponses to extracellular Ca2+, but also by sensing L-amino 
acids [72]. Under physiological conditions, L-amino acids, 
especially aromatic amino acids (e.g., L-Phe), as well as 
short aliphatic and small polar amino acids [73], potentiate 
the high [Ca2+]o-elicited activation of the CaSR by altering 
the EC50 values required for [Ca
2+]o-evoked [Ca
2+]i re-
sponses and its functional cooperativity [72,73]. The intra-
cellular Ca2+ mobilization induced by L-amino acids at the 
threshold level of extracellular Ca2+ concentration is char-
acterized by slow oscillations with a frequency at around 
12 peaks min1 [74]. Distinctive signaling pathways trig-
gered by amino acids compared with extracellular Ca2+ have 
been confirmed in quite a few studies [74]. However, the 
specific binding pocket(s) for amino acids are still unclear 
due to the lack of structural information of the CaSR and 
the low binding affinity (in the mmol L1 range) of the lig-
ands.  
Sequence alignment of the CaSR with conserved amino 
acid residues that are involved in the binding of glutamate 
to mGluRs was applied as an initial approach to identify the 
potential L-Phe binding site [75]. Zhang et al. [75] demon-
strated that mutating three adjacent Ser to Ala eliminated 
L-Phe potentiated receptor activity measured by cell popu-
lation assay of changes in Ca2+i using fluorimetry. In 2004 
and 2005, Mun et al. [76] published two papers about 
L-amino acid-sensing in the CaSR. In their 2004 study, they 
confirmed the binding site for amino acids was within the 
VFT domain of the CaSR by utilizing CaSR-mGluR chi-
meric receptor constructs. The receptor lacking the CaSR 
ECD exhibited impaired response to L-amino acids. One 
year later, using mutagenesis and cell population studies, 
they showed that two residues, Thr145 and Ser170, could be 
crucial for sensing L-amino acids, since a double mutant of 
the CaSR, T145A/S170T, selectively failed to respond to 
L-Phe [77]. Recently, our lab reported an L-Phe binding site 
near the previously predicted calcium-binding Site 1 based 
on computational docking results and mutational studies 
using both single and cell population assays of recep-
tor-induced changes in Ca2+i [70]. We found that the poten-
tial L-Phe-binding site is comprised of residues Leu51, 
Thr145, Ser170, Tyr218 and Ser272 and was responsible for 
positive heterotropic cooperativity between extracellular 
Ca2+ and L-Phe [70].     
3.3  The binding of allosteric modulators to the CaSR 
Distinct from L-amino acids, the allosteric modulators of 
the CaSR, many of which have a phenylalkylamine struc-
ture, have been proposed to regulate the CaSR’s activity via 
interacting with its transmembrane domains instead of the 
extracellular domain [71,78,79]. Hauache et al. [12] made 
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truncation and deletion mutants of the CaSR and engineered 
a chimeric protein with the ECD domain of the CaSR and 
the 7TM of mGluR1. Their results showed that the positive 
allosteric modulator of the CaSR, R-568, was effective in 
constructs with the 7TM from the CaSR but not in the ones 
with the mGluR1 7TM instead. Two years later, the same 
lab reported that an acidic residue, Glu837, in extracellular 
loop 3 was involved in the interaction with NPS R-568, as 
the CaSR mutant E837A abolished the NPS R-568-    
potentiated receptor activity while maintaining partial 
Ca2+-sensing capability [71]. Two independent studies have 
used homology modeling of the 7TM domain of the CaSR 
based on the X-ray structure of rhodopsin to predict the po-
tential binding site for the allosteric modulators. Miedlich et 
al. [79] found that mutations on residues Phe668, Arg680, 
Phe684 and Glu387 altered the CaSR’s response to 
NPS2143, which is a negative allosteric modulator of the 
CaSR, suggesting their involvement in binding the drug. 
Petrel et al. [78] independently revealed that the binding 
pockets for calcimimetics and calcilytics were both located 
on the 7TM domain. They partially overlap with residues 
Trp818, Phe218, Glu837 and Il3841, but are not identical to 
the residues predicted in the other study. The recognition of 
calcilytics also involved residues in TM3 and TM5.  
3.4  Physiological relevance of studying ligand binding 
in vitro 
In biological systems, free L-amino acids are essential mol-
ecules since they not only serve as the building blocks of 
proteins but also are the metabolic precursors of crucial 
substances that serve as ligands for receptors [80]. Evidence 
for the presence of amino acid-sensing mechanisms in var-
ious studies, e.g., regulating insulin secretion from pancre-
atic B cells, hepatic autophagy, etc., suggest the widespread 
existence of amino acid sensors, although the identities of 
these amino acid sensors are in many cases unknown. These 
findings highlight amino acid-dependent control of cellular 
signal transduction pathways. Fluctuation of the plasma 
levels of amino acids can, therefore, regulate the rate of 
hormone synthesis and secretion as well as Ca2+ metabolism, 
among other processes [80]. The CaSR is present through-
out the gastrointestinal tract [17,81], including in gas-
trin-secreting antral G cells and cholecystokinin-secreting l 
cells, both of which are known to be activated by both 
[Ca2+]o and aromatic amino acids [81]. L-amino acids, es-
pecially aromatic amino acids, are known to enhance the 
sensitivity of the CaSR to [Ca2+]o, which could be one po-
tential explanation for how dietary protein modulates 
[Ca2+]o homeostasis in normal individuals as well as in pa-
tients with chronic renal failure [80,82].  
The amino acid concentrations in plasma before and after 
a meal are listed in Table 1. All of them are within the mol 
L1 range. Even after a steak meal, the peak value for cer-
tain amino acids (e.g., Gly) is around 0.5 mmol L1 [83]. 
However, the reported EC50 for activation of the CaSR by 
L-Phe was 3.5 mmol L1 as measured by intracellular cal-
cium readout from the CaSR-transfected HEK293 cells [73]. 
The discrepancy for these phenomena relies on the fact that 
in physiological conditions, the receptors are stimulated by 
a mixture of amino acids, small peptides as well as proteins 
instead of a single amino acid. In fact, small peptides, for 
instance, -glutathione and its variants, have lower EC50s (in 
the range of mol L1) compared with L-Phe or L-Trp (Ta-
ble 2). 
Conigrave et al. [73] have investigated the physiological 
relevance of their in vitro findings regarding the amino acid 
concentration dependence of the CaSR. They mixed 20 
common L-amino acids at similar concentration compared 
to those present in fasting human plasma and showed that 
the mixture could reproduce the effects of high concentra-
tions of single amino acids. These findings suggest that the 
CaSR sensing L-amino acid is a universal property and the 
amino acid composition of human plasma has a pronounced 
effect on the activity of the CaSR compared to single amino 
acids.  
The metabolism of both Ca2+ and amino acids will be 
re-appraised in the context of protein ingestion and dietary 
supplements, since L-amino acid and Ca2+ can potentiate the 
sensing capability by the CaSR for each other. It was also 
emphasized by Conigrave et al. [73] that the CaSR should  
Table 1  Plasma amino acid concentrations before and during intravenous amino acid infusion and after an oral steak meal (mol L1) 
Amino acid infused IV Basal 060 min 61120 min 121180 min 181240 min Steak meal 
Phe 51±5 68±8 90±7* 103±14* 198±37* 85±7 
Trp 49±5 66±6 97±8* 140±16* 244±38* 94±9 
Gly 283±50 291±49 315±50* 417±75* 559±98 386±53 
Ala 316±16 345±15 353±25 326±10 365±31 549±50 
His 80±14 104±8 130±10 172±19 316±25 100±11 
a) *, Time period when gastric acid secretion was significantly greater than saline control. Mean (±SE) plasma amino acid concentrations of phenylala-
nine, tryptophan, glycine, alanine, and histidine before (basal) and in response to intravenous infusion of each individual amino acid and after the steak meal. 
Each amino acid was infused in 125 mL for 1 h in increasing stepwise manner; doses of Phe, Gly, Ala, and His were 0.0125, 0.025, 0.05, and 0.1 mol L1, 
respectively, and doses of Trp were 0.005, 0.01, 0.02, and 0.04 mol L1. The steak meal contained 49 g protein and 405 kcal (table adopted from [83]). 
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Table 2  Potencies of -glutamyl peptides for [Ca2+]i mobilization in 
CaSR-expressing HEK-293 cells 
-Glutamyl peptide EC50 for peptide (mol L1) 
S-Methylglutathione 1.7±0.5 (n=4) 
Glutathione 3.9±0.7 (n=4) 
-Glu-Cys 4.7±0.9 (n=3) 
-Glu-Ala 4.8±0.7 (n=3) 
a) HEK-293 cells that stably express the CaSR were loaded with 
fura-2AM and assayed for receptor-dependent intracellular Ca2+ mobiliza-
tion by microfluorimetry. The data were obtained from cells perfused with 
physiological saline solution in the presence of 2.5 mmol L1 [Ca2+]o. In the 
accompanying experiments, the EC50 for L-Phe was 1.1±0.5 mmol L
1 
(n=4) (table adopted from [84]. 
be reassessed as a potential target of aromatic L-amino acids 
under certain toxic metabolic conditions. For instance, the 
CaSR expressed in the CNS might be involved in contrib-
uting to the toxic effects resulting from the elevated levels of 
L-Phe in phenylketonuria or in hepatic encephalopathy.  
4  Proteins interacting with the CaSR 
In addition to heterotrimeric G proteins, the CaSR needs to 
recruit a number of other proteins to ensure that signaling 
networks are fully functional. Recently, a few of these pro-
teins have been identified using the yeast two-hybrid system 
and/or co-immunoprecipitation studies. The absence of 
these proteins would, in turn, influence the CaSR signaling. 
Filamin A has been demonstrated to interact with the 
C-terminal of the CaSR in 2001 by two individual groups 
[61,62]. Later studies using truncation and deletion mutants 
revealed that the binding took place in a two -strands re-
gion from amino acid 962 to 981 of the CaSR. Blocking the 
interaction between Filamin A and the CaSR attenuated 
CaSR-induced ERK activity [61]. The binding of the two 
proteins also exhibited importance in CaSR-mediated Rho 
signaling [85,86] as well as JNK activation [87]. Studies in 
a cell line deficient in Filamin A suggested that Filamin A 
might protect the CaSR from degradation [88]. 
Potassium channels (Kir4.2 and Kir4.1) have been re-
ported to colocalize with the CaSR in HEK293 cells stably 
expressing the CaSR as well as in endogenous rat kidney 
tissues [89]. However, how and whether their function can 
be regulated by the CaSR still needs to be elucidated. It is 
possible that Filamin A may act as a bridge that links the 
CaSR with either Kir4.1 or Kir4.2.  
The region between amino acids 880900 of the CaSR 
has been identified to interact with the region 660838 of an 
E3 ubiquitin ligase, dorfin [90]. Overexpression of dorfin is 
believed to increase the ubiquitination of the CaSR, result-
ing in accelerated degradation [90].  
Associated molecule with SH3 domain of STAM 
(AMSH) is an ubiquitin isopeptidase that regulates the sort-
ing of the receptor EGFR [91]. The CaSR C-tail region 
from 895-1075 was found to bind to AMSH [92]. Increasing 
AMSH expression level or stimulating the CaSR with cal-
cium could reduce CaSR expression in HEK293 cells trans-
fected with these two proteins [92,93].       
-arrestins play an important role in modulating the de-
sensitization and internalization of GPCRs through collabo-
rating with G protein receptor kinases (GRK) [94]. Overex-
pression of -arrestins negatively regulates the inositol 
phosphate signaling mediated by the CaSR in HEK293 cells. 
A PKC inhibitor or mutation of the CaSR PKC phosphory-
lation sites reduces the effect of overexpressing -arrestins. 
RAMP is an abbreviation for receptor activity-modifying 
protein, which has been reported to influence receptor traf-
ficking, glycosylation as well as second messenger produc-
tion [95]. Experiments in COS7 cells demonstrated that 
RAMP1 and RAMP3, but not RAMP2, can increase the 
surface expression of the co-transfected CaSR [96]. More-
over, RAMP3 had a greater influence on modulating the cell 
surface expression of the receptor.     
5  Trafficking of the CaSR in cells 
Like many other GPCRs, the trafficking of the CaSR is a 
complex process that involves interacting with various pro-
teins that determine the final destination of the receptor. 
Once synthesized in the endoplasmic reticulum (ER), CaSR 
that is improperly folded will fail the quality control process 
and be shunted toward the proteasome for degradation. Re-
ceptors passing the quality control process will traffic to the 
plasma membrane or other cellular compartments via inter-
action with chaperones and small GTP-binding proteins 
[97100].  
Several proteins interact with the CaSR when the recep-
tor exits from the ER, including p24A (transmembrane 
emp24 domain trafficking protein 2(TMED2)) [101]; the 
small GTP-binding protein Sar1 [102]; receptor-activity- 
modifying proteins (RAMPs) [96]; Rab1 [103]; calmodulin 
(CaM) [63]; 14-3-3 [104] and Dorfin [90]. p24A binds pre-
dominantly to the immature form of the CaSR and cycles 
between the ER, the ER-Golgi intermediate compartment 
(ERGIC) and the cis-Golgi membranes [105,106]. Through 
its interaction with p24A, the stability of the CaSR and its 
plasma membrane targeting will be increased, possibly via 
an increase in total receptor number [101]. Sar1 is another 
protein that is required for releasing the receptor from the 
ER [101,102]. RAMPs and Rab1 are small GTP-binding 
proteins that localize to the cytoplasmic face of organelle 
membranes. Both of them are found to facilitate the CaSR 
trafficking from ER to Golgi [96,103]. The 14-3-3 protein is 
predicted to interact with the arginine-rich domain of the 
CaSR (890RRxxxxRKR898) and may lead to the retention of 
the CaSR in the ER [65,104,107]. There is also a calmodu-
lin-binding site in the C-tail of the CaSR comprising resi- 
dues 874895 [47]. However, the function of CaM still  
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needs to be revealed. It is reported that CaM binds to both 
immature and mature forms of the CaSR, suggesting its role 
in modulating anterograde trafficking of the receptor [63]. 
On the other hand, CaM may stabilize the surface receptor 
on the cell membrane [47]. 
Its interactions with several different proteins contribute 
to the subcellular localization of the CaSR. The association 
of intracellular loops 1 and 3 with caveolins keeps the CaSR 
highly enriched in invaginations of plasma membrane called 
caveolae in certain types of cells, like parathyroid chief cells 
and cardiac myocytes [19,108110]. Filamin A, a scaf-
fold/adaptor protein, has also been shown to interact with 
the C-terminal of the CaSR, targeting the receptor to sites of 
Rho activity [85,86,111]. The CaSR also interacts with in-
tegrins, and the latter may contribute to the regulation of 
cell migration [7].  
The surface expressed CaSR may undergo endocytosis 
initiated by phosphorylation by G protein-coupled receptor 
kinases (GRKs) or protein kinase C [112,113], involving 
-arrestins and facilitated by Rab7, Rab11a and adaptor 
protein-2 (AP2) [93,114,115]. The endocytosed receptors 
are either recycled to the cell membrane, thereby contrib-
uting to the receptor resensitization, or translocated to lyso-
somes for degradation [116,117].  
There are two mechanisms involved in degradation of the 
CaSR. One is mediated by the activity of the E3 ubiquitin 
ligase family member, dorfin. The CaSR will be targeted to 
the proteasome after being ubiquitinated by dorfin [118]. 
The CaSR can also be degraded in lysosomes. A deubiqui-
tinating enzyme specific for k63-linkages (AMSH, which is 
short for associated molecule with the SH3 domain of 
STAM) has been reported to be involved in this process 
[93]. Moreover, the PEST-like sequence in the C-tail of the 
CaSR, which is rich in proline, glutamine, serine and threo-
nine, can also lead the receptor to lysosomes [115].  
In the continuous presence of agonist stimulation, those 
secretory pathways as well as the endocytosis mechanisms 
mentioned above work collaboratively, causing a net in-
crease in CaSR expressed on the plasma membrane. This 
phenomenon was named Agonist-Driven Insertional Sig-
naling (ADIS) [104]. However, a number of questions 
raised by the ADIS mechanism remained to be explored.     
6  The disease-associated CaSR mutations 
The discovery of the CaSR and its role in maintaining 
physiological calcium level led to the identification of dis-
orders of calcium homeostasis that are related to abnormal 
receptor activity. There are more than 200 mutations of the 
CaSR that have been catalogued in the online database at 
http://www.casrdb.mcgill.ca/. The CaSRdb is the primary 
attribution for the CaSR-related disorders [119]. Autoim-
mune antibodies against the CaSR are another cause for 
receptor dysfunction [120122].  
Mutations of the CaSR may lead to an inactive receptor 
or an overactive receptor. The majority of these dis-
ease-associated mutations are missense mutations, with sin-
gle amino acid substituted. Amino acids insertion, deletion, 
open reading frame shift and splice-site mutations have also 
been reported [119].  
The disorders associated with inactive receptors include 
cases of familial hypocalciuric hypercalcemia (FHH), which 
in more severe cases can be associated with dominant nega-
tive activity of the mutant CaSR [123] as well as a more 
serious disorder known as neonatal severe hyperparathy-
roidism (NSHPT), most commonly due to inactivating mu-
tations in both copies of the CaSR gene [120]. Mild to 
moderate hypercalcemia (no more than 20% above the up-
per limit of normal of the serum calcium level) and unusu-
ally high renal tubular reabsorption of calcium are the key 
clinical features of FHH [119]. On the other hand, NSHPT 
is a rare disorder characterized by marked symptomatic hy-
percalcemia and usually occurs in children younger than 6 
months. NSHPT can cause multiple fractures, neurodevel-
opmental disorders and even death.  
The disorders associated with the CaSR activating muta-
tions include autosomal dominant hypocalcemia (ADH) 
[124] and Bartter syndrome type V [125]. Patients with 
ADH usually do not show symptoms but have mild reduc-
tions in calcium concentration in the blood. Seizures may 
happen to younger patients, often occurring during febrile 
episodes. Serum PTH levels are generally within or near the 
lower limit of the normal range. Calcium concentration in 
the urine is higher than in hypoparathyroid patients of other 
etiologies. Bartter’s syndrome subtype V is associated with 
severe heterozygous activating mutations in the CaSR. Pa-
tients with Bartter syndrome type V show symptoms like 
hypokalemic metabolic alkalosis and hyperaldosteronism 
along with hypocalcemia [125]. 
Hannan et al. [126] have reported that the majority 
(>50%) of their newly identified CaSR mutations in patients 
with FHH, NSHPT and autosomal dominant hypocalcemic 
hypercalciuria are missense substitutions within the ECD of 
the CaSR. Combining their study with previously reported 
disease-associated the CaSR mutations, here we show that 
the bilobed VFTD plays a pivotal role in interacting with 
Ca2+ and regulating the function of the CaSR, as more than 
half of the mutations occurred in the ECD (Figure 3C). By 
analyzing the homology modeled structure of the CaSR, our 
studies further revealed that >50% of these mutations are 
situated within 10 Å of one or more calcium-binding sites 
[126]. Moreover, since a substantial percentage (>50%) of 
the mutations near calcium-binding sites are located at Site 
1, the importance of VFTD cleft is highlighted. The rest of 
the calcium-binding sites can possibly play an auxiliary role 
by building molecular connectivity between Site 1 as well 
as other calcium-binding sites and thereby enhancing posi-
tive cooperativity [70].  
Recently, studies have appeared showing that disorders  
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Figure 3  Mapping the disease-associated mutations on the modeled CaSR ECD. A, Overlay of modeled structure of Ca2+-sensing receptor with crystal 
structures of mGluR1, mGluR3 and mGluR5. The modeled CaSR extracellular domain (ECD), highlighted in yellow, is based on mGluR1 (pdb: 1EWK). 
mGluR1 (pdb:1EWK) is highlighted in green, mGluR3 (pdb:2E4U) is highlighted in cyan, mGluR5 (pdb:3LMK) is highlighted in violet. Calcium is labeled 
in red, L-Phe is in purple [68]. B, The zoom in view of the hinge region. Purple: L-Phe; orange: glutamate. C, Disease-related CaSR mutations on ECD. 
Cyan: the modeled structure of the CaSR ECD; purple: residues involved in disease-associated mutations reported in the recent studies by Hannan et al.; 
yellow: residues involved in predicted calcium binding pockets.  
with an FHH or ADH phenotype may not directly involve 
mutations of the CaSR, but can be associated with muta-
tions of other proteins that participate in CaSR-mediated 
signaling [114,127]. Familial hypocalciuric hypercalcemia 
type 2 (FHH2) and familial hypocalciuric hypercalcemia 
type 3 (FHH3) are genetically distinct, autosomal dominant 
disorders of extracellular calcium homeostasis in the ab-
sence of mutations in the CaSR. The first form of FHH 
identified, caused by mutations of the CaSR gene on chro-
mosome 3q21.1, is now called familial hypocalciuric hy-
percalcemia type 1 (FHH1). The loci for FHH2 and FHH3, 
in contrast, are located on chromosomes 19p and 19q13.3 
respectively [114]. Loss-of-function mutations of G-protein 
subunit-α11 (GNA11) cause FHH2, and loss-of-gain muta-
tions of the sigma subunit of adaptor protein-2 (AP2), a 
central component of clathrin-coated vesicles (CCVs), de-
crease the sensitivity of CaSR to extracellular calcium 
changes, in association with reduced CaSR endocytosis, and 
lead to FHH3 [114,127]. Conversely, in addition to the first 
form of ADH identified, now called ADH type 1, which is 
due to activating mutations of the CaSR as noted above, 
ADH type 2 is caused by gain-of-function mutations of 
G-protein subunit-α11 (GNA11). Gain-of-function muta-
tions of adaptor protein-2 sigma subunit (AP2σ2) represent 
a theoretically possible cause of ADH, but have not been 
identified as of yet [127]. 
7  Conclusion and future perspectives 
Throughout this review, the molecular characteristics that 
contribute to the structural biology of the CaSR in 
[Ca2+]o-sensing and Ca
2+ signaling have been summarized. 
On the way to providing advanced information about the 
structural features related with this receptor as well as other 
proteins in GPCR family C, researchers will continue to 
face several challenges.  
First, the CaSR is a membrane protein, so the challenges 
associated with studying membrane proteins may also occur 
with the CaSR. Membrane proteins are difficult to separate 
from the cells due to their hydrophobic transmembrane do-
mains. Secondly, although X-ray crystallography has been 
used as one of the major tools to study the structure of pro-
teins, application of this technique to the crystallization of 
glycosylated proteins exhibits its own limitations. Like oth-
er glycosylated proteins, the complex form of the glycans 
on the CaSR can prevent crystallization of this protein be-
cause the chemical and conformational heterogeneity of the 
glycoproteins usually inhibit crystallization. Thirdly, due to 
the limitation of the conditions for crystallization as well as 
the fast on and off rate of Ca2+ when its interaction belongs 
to weak binding, even in some proteins that have had their 
crystal structure solved like mGluR1, the detection of 
Ca2+-binding sites in those proteins may be still elusive. 
Moreover, the selectivity of the CaSR for different amino 
acids is not clear and the interaction between amino acids 
and the CaSR are relatively weak (in mmol L1 range). 
Fourthly, currently, methods for direct measurement of Ca2+ 
and amino acid binding to the CaSR have not yet been well 
established, nor are there methods for directly monitoring 
ligand induced conformational changes of the proteins. Ap- 
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Figure 4  Summary of research approaches. 
proaches for addressing these questions rely on indirect 
measurements of calcium-induced intracellular signaling 
changes in living cells or utilizing the fluorescence reso-
nance energy transfer (FRET) assay for monitoring lig-
and-generated fluorescence changes in isolated proteins. 
Last but not least, the large size of the protein (extracellular 
domain 612 amino acids; whole protein 1078 amino acids) 
as well as the fact that the CaSR functions as a dimer con-
tribute to the difficulties in studying the protein, especially 
when it possesses a high Hill coefficient which suggests 
possible multiple binding sites for ligands.  
However, these challenges can be overcome by innova-
tive experimental designs and advanced technologies. In our 
lab, we have utilized a grafting approach, subdomain ap-
proach and intact cell studies to probe the potential calci-
um-binding sites on the extracellular domain of CaSR and 
the functional cooperativity among them (Figure 4). Amino 
acid-selective isotopic labeling of proteins will be applica-
ble to structural studies of proteins that are not amenable to 
traditional NMR studies [128]. Various Ca2+ sensors can be 
employed to monitor intracellular calcium signaling and 
further understand how different allosteric modulators as 
well as drugs for the CaSR regulate the receptor function. A 
better understanding of the molecular properties of the 
CaSR using cutting edge technologies is in demand to pro-
vide greater therapeutic approaches since the receptor is 
involved in various physiological functions.  
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